Taking their inspiration from nature, scientists at the University of New South Wales have developed a new method for carrying out chemical reduction - an industrial process used to produce fuels and chemicals that are vital for modern society. [ + ]

Research Australia has formed a collaborative international alliance with three advocacy groups. [ + ]

CSIRO and the Australian National University have launched a new centre for biodiversity research. [ + ]

The 2013 round of funding from the Australian Cancer Research Foundation is now open. [ + ]

Phosphagenics (ASX:POH) and Japan’s Nippon Zoki have progressed to the negotiation stage in their tie-up to produce an anti-inflammation product for the US market. [ + ]

At least $200 million will be invested in start-up companies under the latest tranche of the federal government’s Innovation Investment Fund. [ + ]

AusBiotech’s March industry submission addresses the Therapeutic Goods Administration’s (TGA) proposed changes to the pre-market assessment requirements for medical devices. [ + ]

The class of HER2/neu breast cancer vaccines to which Biolife Science’s HER-Vaxx belongs has been endorsed in a key breast cancer journal. [ + ]

Calzada’s (ASX:CZD) PolyNovo unit has wrapped up a human trial involving using NovoSorb in vacuum-assisted closure of pressure sores. [ + ]

pSivida licensee Alimera Sciences has made a resubmission to the US Food and Drug Administration for approval of Iluvien for chronic diabetic macular edema. [ + ]

Rice University researchers have found an unexpected link between a protein that triggers the formation of blood clots and other proteins that are essential for the body’s immune system. The find could lead to new treatments for thousands of patients who suffer from inflammatory diseases and disorders that cause abnormal blood clotting. [ + ]

A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection. [ + ]

New research has identified more than 80 genetic variations that can increase a person’s risk of prostate, breast and ovarian cancers. [ + ]

Bioniche (ASX:BNC) is back in control of commercialisation activities for bladder cancer treatment Urocidin after wrapping up its partnership with Endo Pharmaceuticals. [ + ]

Bioniche (ASX:BNO) has lauded decisions by the Canadian government to provide more funding for programs which support R&D and commercialisation efforts by the nation’s companies. [ + ]